Furthermore, increased serum sclerostin levels were associated with decreased cardiovascular events in CKD patients (p = 0.02) [58] and low short-term (18-month) cardiovascular mortality in dialysis patients [59]. The gene discussed is SOST; the disease is chronic kidney disease.